In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
Ann Intern Med. 2021 Jan 05;:
Authors: Singh A
Abstract
SOURCE CITATION: RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345-52. 33031764.
PMID: 33395331 [PubMed - as supplied by publisher]
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Singh A Tags: Ann Intern Med Source Type: research
MedWorm Privacy Policy
Disclaimer
Copyright © MedWorm 2006-2024